ArticleFrontiers in cardiovascular medicine2026
Fluoroless ablation of right-sided supraventricular tachycardia: a step-by-step approach and retrospective case series.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluoroscopy has long been indispensable in electrophysiology procedures. However, the detrimental long-term effects of x-rays on both patients and healthcare workers are well documented. Moreover, the routine wearing of lead aprons is associated with orthopedic complications in the long term. The emergence of new technologies, such as electroanatomic mapping systems and intracardiac echocardiography, has significantly reduced the need for fluoroscopy, thereby alleviating these concerns. This article describes our step-by-step approach to fluoroless catheter ablation of right-sided supraventricular tachycardia and evaluates its implementation in clinical practice through a retrospective case series. Between May 2024 and April 2025, 86 consecutive patients underwent ablation using this strategy. The findings support existing evidence that zero-fluoroscopy interventions are feasible, efficient and safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.